Cargando…

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review

Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaney, Alexander, Stevens, Andrew, Monk, Paul, Martin, Douglas, Diaz, Dayssy A., Wang, Shang-Jui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213742/
https://www.ncbi.nlm.nih.gov/pubmed/35756663
http://dx.doi.org/10.3389/fonc.2022.932637
_version_ 1784730904076222464
author Yaney, Alexander
Stevens, Andrew
Monk, Paul
Martin, Douglas
Diaz, Dayssy A.
Wang, Shang-Jui
author_facet Yaney, Alexander
Stevens, Andrew
Monk, Paul
Martin, Douglas
Diaz, Dayssy A.
Wang, Shang-Jui
author_sort Yaney, Alexander
collection PubMed
description Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of de novo oligometastatic, oligorecurrent and oligoprogressive prostate cancer.
format Online
Article
Text
id pubmed-9213742
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92137422022-06-23 Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review Yaney, Alexander Stevens, Andrew Monk, Paul Martin, Douglas Diaz, Dayssy A. Wang, Shang-Jui Front Oncol Oncology Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of de novo oligometastatic, oligorecurrent and oligoprogressive prostate cancer. Frontiers Media S.A. 2022-06-08 /pmc/articles/PMC9213742/ /pubmed/35756663 http://dx.doi.org/10.3389/fonc.2022.932637 Text en Copyright © 2022 Yaney, Stevens, Monk, Martin, Diaz and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yaney, Alexander
Stevens, Andrew
Monk, Paul
Martin, Douglas
Diaz, Dayssy A.
Wang, Shang-Jui
Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title_full Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title_fullStr Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title_full_unstemmed Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title_short Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
title_sort radiotherapy in oligometastatic, oligorecurrent and oligoprogressive prostate cancer: a mini-review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213742/
https://www.ncbi.nlm.nih.gov/pubmed/35756663
http://dx.doi.org/10.3389/fonc.2022.932637
work_keys_str_mv AT yaneyalexander radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview
AT stevensandrew radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview
AT monkpaul radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview
AT martindouglas radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview
AT diazdayssya radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview
AT wangshangjui radiotherapyinoligometastaticoligorecurrentandoligoprogressiveprostatecanceraminireview